Search Results

You are looking at 31 - 40 of 250 items for :

  • "steatosis" x
  • All content x
Clear All
Free access

Galya Vassileva, Weiwen Hu, Lizbeth Hoos, Glen Tetzloff, Shijun Yang, Li Liu, Ling Kang, Harry R Davis, Joseph A Hedrick, Hong Lan, Timothy Kowalski, and Eric L Gustafson

insulin administration ( Fig. 4 B). Increased liver steatosis in Gpbar1 −/− males on HFD After 8 weeks on HFD, Gpbar1 + / + and Gpbar1 −/− male and female mice were killed, and their livers were collected for histological analysis. As expected

Free access

Elena Grasselli, Adriana Voci, Ilaria Demori, Laura Canesi, Rita De Matteis, Fernando Goglia, Antonia Lanni, Gabriella Gallo, and Laura Vergani

Introduction Hepatic steatosis refers to an excess accumulation of lipids, primarily triglycerides (TAGs) and it is a major element of non-alcoholic fatty liver disease (NAFLD; Unger et al . 2010 ). Lipid metabolism is mainly regulated by the

Free access

Srilaxmi Kalavalapalli, Fernando Bril, Joy Guingab, Ariana Vergara, Timothy J Garrett, Nishanth E Sunny, and Kenneth Cusi

well as cardiovascular disease from a more unfavorable cardiovascular risk profile ( Charlton et al. 2011 ). Abnormal mitochondrial oxidative metabolism is a central feature for the transition from isolated steatosis to NASH ( Sunny et al. 2010

Free access

Hong Xu, Yang Zhou, Yongxia Liu, Jian Ping, Qiyang Shou, Fangming Chen, and Ru Ruo

glycogenolysis and gluconeogenesis ( Radziuk & Pye 2001 ). Nonalcoholic fatty liver disease (NAFLD) is a spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which may progress to cirrhosis. NAFLD is strongly associated with

Free access

Gabriel Forn-Cuní, Monica Varela, Conrado M Fernández-Rodríguez, Antonio Figueras, and Beatriz Novoa

diseases are part of a condition termed metabolic syndrome. The hepatic component of metabolic syndrome is non-alcoholic fatty liver disease (NAFLD). This term comprises a wide range of progressive liver injuries including bland steatosis, variable degrees

Free access

Jiean Xu, Qiuhua Yang, Xiaoyu Zhang, Zhiping Liu, Yapeng Cao, Lina Wang, Yaqi Zhou, Xianqiu Zeng, Qian Ma, Yiming Xu, Yong Wang, Lei Huang, Zhen Han, Tao Wang, David Stepp, Zsolt Bagi, Chaodong Wu, Mei Hong, and Yuqing Huo

.05 and ** P  < 0.01 for Adk ∆VEC vs Adk WT (unpaired two-tailed Student's t test). Endothelial Adk deficiency attenuates HFD-induced hepatic steatosis Metabolic alterations in livers of HFD-fed Adk ∆VEC mice were further

Free access

Azusa Sameshima, Tsutomu Wada, Tetsuo Ito, Ayaka Kashimura, Kanae Sawakawa, Rika Yonezawa, Hiroshi Tsuneki, Yoko Ishii, Masakiyo Sasahara, Shigeru Saito, and Toshiyasu Sasaoka

.e.m. ( n =5–7). ** P <0.01 significantly different from the control; †† P <0.01 significant difference between the OVX-HF and Tene groups. Teneligliptin attenuated hepatic steatosis in the mouse model of postmenopausal obesity In order to further clarify

Free access

Isabel Huang-Doran, Alison Sleigh, Justin J Rochford, Stephen O'Rahilly, and David B Savage

worsen hepatic steatosis in murine lipodystrophy models ( Kim et al . 2003 ), raising concerns about their utility in this scenario. Visceral versus subcutaneous fat A striking feature of the lipodystrophy syndromes is the clinical heterogeneity

Free access

Elena Grasselli, Adriana Voci, Laura Canesi, Fernando Goglia, Silvia Ravera, Isabella Panfoli, Gabriella Gallo, and Laura Vergani

steatosis. Once entering the cell, THs mostly bind to specific nuclear receptors (TRs) acting as ligand-dependent transcription factors (‘receptor-mediated’ effects). In humans and rodents, TRs are encoded by two genes, Thra and Thrb , each encoding

Free access

Maria Namwanje, Longhua Liu, Michelle Chan, Nikki Aaron, Michael J Kraakman, and Li Qiang

mass and adipocyte size. In addition, the double-knockout mice, Cbp/p300-AKO , exhibited severe lipodystrophy accompanied by hyperglycemia, hyperlipidemia and hepatic steatosis. Furthermore, we demonstrated that selective inhibition of Cbp and p300